News

PepGen has begun its phase 2 CONNECT1-EDO51 trial, dosing the first patient with PGN-EDO51, an agent for Duchenne muscular dystrophy amendable to an exon 51 skipping.

The study suggests a potential link between poor oral health and changes in brain health, emphasizing the importance of oral care.

Neurology News Network for the week ending February 24, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 23, 2024.

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided perspective on the approval of tofersen (Qalsody; Biogen) for patients with ALS and the ways neurofilament light will be used going forward. [WATCH TIME: 3 minutes]

A recent phase 3 trial demonstrated that N-acetyl-l-leucine significantly improved symptoms in patients with Niemann-Pick disease type C, showing promise as a potential treatment.

The executive director of the Lead (Leaders Engaged on Alzheimer’s Disease) Coalition provided thoughts on the journey and lessons learned from aducanumab (Aduhelm) following Biogen’s decision to remove it from market. [WATCH TIME: 8 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Stephen From. [LISTEN TIME: 22 minutes]

A recent observational study detected anti-DLAT antibodies in the serum of patients with chronic inflammatory demyelinating polyneuropathy with a sensory-dominant phenotype.

The associate professor of neurology at Brown University talked about findings from an observational study investigating treatment options antiplatelets and anticoagulation for cervical artery dissection. [WATCH TIME: 8 minutes]

After a positive phase 1 study, DNL788, an RIPK1 inhibitor, failed to distinguish itself from placebo in HIMALAYA.

The associate professor of neurology at Columbia University talked about a track session that he will be chairing at the upcoming MDA conference on amyotrophic lateral sclerosis genetic research. [WATCH TIME: 5 minutes]

In a cohort of nearly 250 patients with chronic or episodic migraine, less than 2% of patients experienced adverse events while on combination treatment.

The medical director of the Stroke Center at Weill Cornell Medicine talked about results from a recent study on the risk of stroke in patients on assisted reproductive technologies during delivery hospitalization. [WATCH TIME: 4 minutes]

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute discussed several topics related to ALS research and the emerging biomarkers in recent years ahead of the 2024 MDA Clinical and Scientific Conference.

A recent review of studies indicated that intravenous immunoglobulin could be as effective as other treatments in improving disability for patients with chronic inflammatory demyelinating polyradiculoneuropathy.

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on a recently conducted study showing the benefits of timely treatment through mobile stroke units for patients with acute intracerebral hemorrhage. [WATCH TIME: 6 minutes]

Stephen Samples, MD, provided perspective as the newly appointed chair of neurology at Allegheny Health Network, and the responsibilities that come with constructing an effective neurology department.

IVIg and SCIg exhibit differing effects on cytokine profiles in CIDP, potentially due to their distinct pharmacokinetics.

A recent study revealed that elevated L1CAM-positive extracellular vesicle α-synuclein levels in the blood could indicate an increased risk of developing Parkinson disease and related dementia.

The director of Dysautonomia Clinic talked about the importance of focusing beyond migraine to address often overlooked comorbidities such as dysautonomia, hypermobility spectrum disorders, and mast cell activation syndrome. [WATCH TIME: 10 minutes]

Atogepant demonstrated notable efficacy in reducing monthly migraine days compared with placebo, in addition to maintaining a well-tolerated and safe profile.

The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided comments on her session track at the upcoming 2024 MDA conference and some of the recent advancements in ALS research. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

In addition the reductions in the number of new gadolinium-enhancing lesions, frexalimab lowered plasma levels of neurofilament light and CXCL13, a biomarker of inflammatory activity.

The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

A recent study highlighted the potential of susceptibility-weighted image features as imaging biomarkers to differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder.